



**FOLEY
HOAG** LLP
ATTORNEYS AT LAW

**RECEIVED
CENTRAL FAX CENTER
MAY 04 2006**

Fax

Date: May 4, 2006

To: U.S. Patent and Trademark Office Fax #: 571-273-8300 Confirm#: 571-272-1149

Client Matter#: 24922-6401 (ISA-064.01)

Jennifer A. Zarutskie,

From: Ph.D.

Sender's Number: 1754

User #: 1060

Total Pages Sent (Including Cover Sheet): 3

Office: Boston

Message


Re: U.S. Patent Application No.: 09/920,306
Filed: August 2, 2001
Entitled: *Peptides Capable of Functioning as Mimotypes
for Hormonal Analytes*
Applicant: **Inverness Medical Switzerland GmbH**
Inventors: Badley, R. A. *et al.*
Our Reference No.: ISA-064.01 (24922-6401)

Sir/Madam:

Transmitted herewith for filing in connection with the above-referenced patent are the following:

1. Executed Revocation of Power of Attorney with New Power of Attorney and Change of Correspondence Address (1 page); and
2. Executed Statement Under 37 CFR 3.73(b) (1 page).

Sincerely,


Jennifer A. Zarutskie
Reg. No. 50,558

JAZ/rc
Attachments

IMPORTANT - PLEASE READ

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

IF THERE ARE ANY PROBLEMS WITH THIS TRANSMISSION PLEASE TELEPHONE THE SENDER.

Seaport World Trade Center West / 155 Seaport Blvd. / Boston, MA 02210-2600 / TEL: 617.832.1000 / FAX: 617.832.7000
Foley Hoag LLP BOSTON WASHINGTON, DC www.foleyhoag.com

PTO/SB/82 (09-04)

Approved for use through 11/30/2005. OMB 0651-0035
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	09/920,306	RECEIVED CENTRAL FAX CENTER MAY 04 2006
	Filing Date	02-Aug-2001	
	First Named Inventor	Badley	
	Art Unit	1641	
	Examiner Name	Venci, David	
	Attorney Docket Number	ISA-064.01	

I hereby revoke all previous powers of attorney or authorizations of agent given in the above-identified application:

☐ A Power of Attorney is submitted herewith.
OR
☒ I hereby appoint the practitioners at Customer Number : 25181

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with Customer Number: 25181

OR


<input type="checkbox"/> Firm or Individual Name				
Address				
City		State		ZIP
Country				
Telephone		Fax		

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature			
Name	Paul T. Hempel, Esq.		
Date	4/12/06	Telephone	(781) 314-4028

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☒ *Total of 1 form is submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/98 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Inverness Medical Switzerland GmbHApplication No./Patent No.: 09/920,308Filed/Issue Date: August 2, 2001Entitled: Peptides Capable of Functioning as Mimotypes for Hormonal AnalytesInverness Medical Switzerland GmbHa corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title, and interest

The extent (by percentage) of its ownership interest is _____ %

In the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Bradley, R. A. et al.To: Unilever Patent Holdings BVThe document was recorded in the United States Patent and Trademark Office at Reel 012606, Frame 0787, or for which a copy thereof is attached.2. From: Unilever Patent Holdings Ltd. and Conopco, Inc.To: Inverness Medical Switzerland GmbHThe document was recorded in the United States Patent and Trademark Office at Reel 012312, Frame 0652, or for which a copy thereof is attached.3. From: Unilever Patent Holdings BV Conopco, Inc.To: Inverness Medical Switzerland GmbHThe document was recorded in the United States Patent and Trademark Office at Reel 012607, Frame 0316, or for which a copy thereof is attached.☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.




Signature

Paul T. Hempel, Esq.

Printed or Typed Name

General Counsel

Title



Date

781-314-4028

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.